Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02597062 · OUTCOME

Overall Survival

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma · Source last updated 2023-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
3 years

What was measured

Median time to death in months will be reported

Analysis population: All treated patients

Groups in this outcome

Carfilzomib Plus Cyclophosphamide Plus Dexamethasone

20 mg/m2 day 1 of first cycle then escalated to 70 mg/m2 for all subsequent doses) given on days 1, 8, and 15 of a 28 day cycle plus weekly oral dexamethasone (\< 70 years, 40 mg; ≥ 70 years 20mg) and cyclophosphamide 300 mg/m2 capped at 500 mg Carfilzomib Cyclophosphamide Dexamethasone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Carfilzomib Plus Cyclophosphamide Plus Dexamethasone75

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Carfilzomib Plus Cyclophosphamide Plus Dexamethasone27.43Not reported22.0533.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        22.05
        upper Limit
        33.8
        value
        27.43
denoms
  1. counts
    1. group Id
      OG000
      value
      75
    units
    Participants
description
Median time to death in months will be reported
dispersion Type
95% Confidence Interval
groups
  1. description
    20 mg/m2 day 1 of first cycle then escalated to 70 mg/m2 for all subsequent doses) given on days 1, 8, and 15 of a 28 day cycle plus weekly oral dexamethasone (\< 70 years, 40 mg; ≥ 70 years 20mg) and cyclophosphamide 300 mg/m2 capped at 500 mg Carfilzomib Cyclophosphamide Dexamethasone
    id
    OG000
    title
    Carfilzomib Plus Cyclophosphamide Plus Dexamethasone
param Type
MEDIAN
population Description
All treated patients
reporting Status
POSTED
time Frame
3 years
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice